Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI
FDA Confirms Paragraph IV Patent Litigation for Revefenacin Inhalation Solution
(Reuters) - Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.